NO20043381L - Peptider og peptidommetics med antiproliferativ aktivitet og/eller som forsterker nukleinsyreskadende midler eller behandlinger - Google Patents
Peptider og peptidommetics med antiproliferativ aktivitet og/eller som forsterker nukleinsyreskadende midler eller behandlingerInfo
- Publication number
- NO20043381L NO20043381L NO20043381A NO20043381A NO20043381L NO 20043381 L NO20043381 L NO 20043381L NO 20043381 A NO20043381 A NO 20043381A NO 20043381 A NO20043381 A NO 20043381A NO 20043381 L NO20043381 L NO 20043381L
- Authority
- NO
- Norway
- Prior art keywords
- peptides
- nucleic acid
- peptidometics
- treatments
- acid damaging
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000816 peptidomimetic Substances 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Peptider og peptidomimetika for. behandling av celleproliferative. lidelser assosiert med benigne og. malignante tumorceller. G2. cellesyklus kontrollpunkt.Det beskrives forbindelser inkludert peptider og peptidomimetika som kan benyttes for å behandle celleproliferative lidelser som de som er assosiert med benigne og malignante tumorceller.Mens oppfinnelsen ikke er begrenset til noen spesiell mekanisme, synes forbindelsene som beskrives i virke i det minste delvis ved l inhibere G2-cellesyklu$kontrollpunktet.Oppfinnelsens forbindelser finner derfor anvendelse for inbibering av celleveksten alene eller ved anvendelse i kombinasjon med en nulcleinsyreskadende behandling for å inhibere cellevekst.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35020802P | 2002-01-17 | 2002-01-17 | |
| PCT/IB2003/000425 WO2003059942A2 (en) | 2002-01-17 | 2003-01-17 | Peptides and peptidomimetics having anti-proliferative activity and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043381L true NO20043381L (no) | 2004-10-12 |
| NO332461B1 NO332461B1 (no) | 2012-09-24 |
Family
ID=23375680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043381A NO332461B1 (no) | 2002-01-17 | 2004-11-17 | Peptider og peptidomimetika med antiproliferativ aktivitet og/eller som forbedrer nukleinsyreskadende midler eller behandlinger. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6995135B2 (no) |
| EP (1) | EP1483290B1 (no) |
| JP (3) | JP4041066B2 (no) |
| KR (2) | KR101103412B1 (no) |
| CN (2) | CN101092455B (no) |
| AT (1) | ATE404584T1 (no) |
| AU (2) | AU2003235576C1 (no) |
| CA (1) | CA2471192C (no) |
| CY (1) | CY1108470T1 (no) |
| DE (1) | DE60322845D1 (no) |
| DK (1) | DK1483290T3 (no) |
| ES (1) | ES2311703T3 (no) |
| HK (1) | HK1069179A1 (no) |
| IL (2) | IL162836A0 (no) |
| NO (1) | NO332461B1 (no) |
| PT (1) | PT1483290E (no) |
| SI (1) | SI1483290T1 (no) |
| WO (1) | WO2003059942A2 (no) |
| ZA (1) | ZA200405455B (no) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1483290T1 (sl) * | 2002-01-17 | 2009-02-28 | Takeda Pharmaceutical | Peptidi in peptidomimetiki, ki imajo antiproliferacijsko aktivnost in/ali okrepijo sredstva ali obdelave, ki poškodujejo nukleinsko kislino |
| ATE520653T1 (de) * | 2002-06-06 | 2011-09-15 | Canbas Co Ltd | Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen |
| US20040109853A1 (en) * | 2002-09-09 | 2004-06-10 | Reactive Surfaces, Ltd. | Biological active coating components, coatings, and coated surfaces |
| US20100233146A1 (en) * | 2002-09-09 | 2010-09-16 | Reactive Surfaces, Ltd. | Coatings and Surface Treatments Having Active Enzymes and Peptides |
| US20100210745A1 (en) * | 2002-09-09 | 2010-08-19 | Reactive Surfaces, Ltd. | Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes |
| US20050058689A1 (en) * | 2003-07-03 | 2005-03-17 | Reactive Surfaces, Ltd. | Antifungal paints and coatings |
| US20090238811A1 (en) * | 2002-09-09 | 2009-09-24 | Mcdaniel C Steven | Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials |
| US20110070376A1 (en) * | 2002-09-09 | 2011-03-24 | Reactive Surfaces, Ltd. | Anti-fouling Paints & Coatings |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| CN1812805A (zh) * | 2003-06-25 | 2006-08-02 | 坎巴斯有限公司 | 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物 |
| US8618066B1 (en) | 2003-07-03 | 2013-12-31 | Reactive Surfaces, Ltd., Llp | Coating compositions having peptidic antimicrobial additives and antimicrobial additives of other configurations |
| JP2007501608A (ja) * | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | 抗癌治療の効力を推定するための感受性試験 |
| US20060286006A1 (en) * | 2005-06-21 | 2006-12-21 | Mcdaniel C S | Method and apparatus for the treatment of fluid waste streams |
| AU2007306927B2 (en) * | 2006-10-11 | 2013-10-03 | Aushealth Corporate Pty Ltd | The use of a DNA damaging agent and a ligand for the treatment of cancer |
| US8629650B2 (en) * | 2008-05-13 | 2014-01-14 | Qualcomm Incorporated | Wireless power transfer using multiple transmit antennas |
| US20100112089A1 (en) * | 2008-05-14 | 2010-05-06 | Takeda Pharmaceutical Company Limited | Peptide compound and use thereof |
| US8388904B1 (en) | 2008-12-22 | 2013-03-05 | Reactive Surfaces, Ltd., Llp | Equipment decontamination system and method |
| FR2942798B1 (fr) * | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
| US20130123196A1 (en) * | 2011-08-31 | 2013-05-16 | New York University | Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics |
| RU2732440C2 (ru) * | 2013-06-24 | 2020-09-16 | Кэнбас Ко., Лтд. | Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями |
| CN113861268A (zh) * | 2014-05-21 | 2021-12-31 | 恩特拉达治疗学股份有限公司 | 细胞穿透肽及其制备和使用方法 |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| WO2016033368A1 (en) | 2014-08-27 | 2016-03-03 | Ohio State Innovation Foundation | Improved peptidyl calcineurin inhibitors |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| US11576946B2 (en) | 2018-01-29 | 2023-02-14 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-NFAT interaction |
| WO2019165183A1 (en) | 2018-02-22 | 2019-08-29 | Entrada Therapeutics, Inc. | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy |
| WO2019217682A1 (en) | 2018-05-09 | 2019-11-14 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| CN114989254B (zh) * | 2022-06-17 | 2023-11-03 | 中山大学 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2385257A1 (en) * | 1999-09-22 | 2001-03-29 | Canbas Co., Ltd. | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| WO2001094411A1 (en) | 2000-06-05 | 2001-12-13 | The Regents Of The University Of California | Peptides modulating protease activated receptors and methods of using same |
| SI1483290T1 (sl) * | 2002-01-17 | 2009-02-28 | Takeda Pharmaceutical | Peptidi in peptidomimetiki, ki imajo antiproliferacijsko aktivnost in/ali okrepijo sredstva ali obdelave, ki poškodujejo nukleinsko kislino |
-
2003
- 2003-01-17 SI SI200331414T patent/SI1483290T1/sl unknown
- 2003-01-17 WO PCT/IB2003/000425 patent/WO2003059942A2/en active IP Right Grant
- 2003-01-17 DK DK03729533T patent/DK1483290T3/da active
- 2003-01-17 AT AT03729533T patent/ATE404584T1/de active
- 2003-01-17 JP JP2003560044A patent/JP4041066B2/ja not_active Expired - Lifetime
- 2003-01-17 KR KR1020077031027A patent/KR101103412B1/ko active IP Right Grant
- 2003-01-17 PT PT03729533T patent/PT1483290E/pt unknown
- 2003-01-17 CA CA2471192A patent/CA2471192C/en not_active Expired - Lifetime
- 2003-01-17 IL IL16283603A patent/IL162836A0/xx active IP Right Grant
- 2003-01-17 CN CN2007101270243A patent/CN101092455B/zh not_active Expired - Lifetime
- 2003-01-17 ES ES03729533T patent/ES2311703T3/es not_active Expired - Lifetime
- 2003-01-17 US US10/347,145 patent/US6995135B2/en not_active Expired - Lifetime
- 2003-01-17 CN CNB038062569A patent/CN100360564C/zh not_active Expired - Lifetime
- 2003-01-17 KR KR1020047011092A patent/KR100863090B1/ko active IP Right Grant
- 2003-01-17 AU AU2003235576A patent/AU2003235576C1/en not_active Expired
- 2003-01-17 DE DE60322845T patent/DE60322845D1/de not_active Expired - Lifetime
- 2003-01-17 EP EP03729533A patent/EP1483290B1/en not_active Expired - Lifetime
-
2004
- 2004-07-01 IL IL162836A patent/IL162836A/en unknown
- 2004-07-08 ZA ZA2004/05455A patent/ZA200405455B/en unknown
- 2004-11-17 NO NO20043381A patent/NO332461B1/no not_active IP Right Cessation
-
2005
- 2005-03-21 HK HK05102425.6A patent/HK1069179A1/xx not_active IP Right Cessation
- 2005-09-06 US US11/221,348 patent/US7476657B2/en not_active Expired - Lifetime
-
2007
- 2007-08-24 JP JP2007218979A patent/JP4873646B2/ja not_active Expired - Lifetime
-
2008
- 2008-10-31 CY CY20081101235T patent/CY1108470T1/el unknown
- 2008-12-04 US US12/328,632 patent/US20090253635A1/en not_active Abandoned
-
2009
- 2009-04-29 AU AU2009201711A patent/AU2009201711B2/en not_active Expired
-
2010
- 2010-11-09 JP JP2010251327A patent/JP2011037896A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043381L (no) | Peptider og peptidommetics med antiproliferativ aktivitet og/eller som forsterker nukleinsyreskadende midler eller behandlinger | |
| ATE369755T1 (de) | Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren | |
| GB9903762D0 (en) | Organic compounds | |
| PT1796660T (pt) | Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta | |
| NO20080075L (no) | Sammensetninger og fremgangsmater for inhibering av JAK-nervefiberkjeden | |
| HUP0301179A2 (hu) | Módosított VIII-as faktor | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| DE602005016198D1 (de) | Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden | |
| AU7548500A (en) | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents | |
| WO2003013554A3 (en) | Aromatase inhibitors from broussonetia papyrifera | |
| DE69902523D1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
| YU11402A (sh) | Nova primena docetaksela za lečenje hepatoma | |
| BG101138A (en) | The use of glyceryltriacetate for the treatment of onychomycosis | |
| EP1407752A4 (en) | COMPOSITE POWDERS AND SKIN PREPARATIONS FOR EXTERNAL USE CONTAINING THESE POWDERS | |
| DE60214207D1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
| WO2008014603A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| WO2020205646A3 (en) | Small molecule parg inhibitors and methods of use thereof | |
| WO2003079748A3 (en) | Potentiation of cancer therapies by znf217 inhibition | |
| DE602008003411D1 (de) | Verwendung von d-ribose zur behandlung von vorhofflimmern | |
| WO2005094282A3 (en) | Combination therapy comprising cloretazinetm | |
| WO2005082353A3 (en) | Use of beta-lapachone for treating or preventing cancer | |
| WO2003094967A3 (en) | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders | |
| Chandra | Effect of 5-fluorouracil on the gibberellic acid-induced formation of thermolabile α-amylase molecules in barley aleurone cells | |
| DE60209533D1 (de) | Entzündungshemmende dermatokosmetische zusammensetzung zur behandlung von akne und seborrhoischer dermatitis | |
| WO2024086708A3 (en) | Compositions and methods for preventing cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Erratum |
Free format text: KORREKT INNGIVELSEDAG ER 2004.08.13. |
|
| MK1K | Patent expired |